Patients diagnosed with coronavirus disease 2019 (COVID-19) become critically ill primarily
around the time of activation of the adaptive immune response. Here, we provide evidence …

Background Data are scarce on immunogenicity of COVID-19 vaccines in patients with
autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to …

Background Disease-specific studies have reported impaired humoral responses after
SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated …

Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

Gram-negative pathogens are a rapidly increasing threat to human health worldwide due to
high rates of antibiotic resistance and the lack of development of novel antibiotics. The …

Objectives Characterisation of the human antibody response to SARS‐CoV‐2 infection is
vital for serosurveillance purposes and for treatment options such as transfusion with …

We compared the performance of SARS-CoV-2 neutralising antibody testing between 12
European laboratories involved in convalescent plasma trials. Raw titres differed almost 100 …

Methods| This is a prospective cohort study conducted at the MS Center Amsterdam in
Amsterdam, the Netherlands. On July 31, 2020, all adult patients with a current diagnosis of …

Background: Patients affected by different types of autoimmune diseases, including common
conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated …

Summary Background Afucosylated IgG1 responses have only been found against
membrane-embedded epitopes, including anti-S in SARS-CoV-2 infections. These …